SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Illustration showing people sitting around world map on globe working with online computer
Job Trends
Employers Warm Up to Remote Workers Again: BioSpace Report
Biopharmas are less focused on local job candidates and are more open to recruiting regardless of location, according to the new BioSpace employment outlook report. Even employers who prefer to hire locally would consider remote hires for some roles.
February 5, 2026
 · 
5 min read
 · 
Angela Gabriel
Trend artwork 3D photo collage sketch image of young sad stressed lady with headache burnout deadline overloaded tired work in office.
Duchenne muscular dystrophy
Sarepta Saga Has ‘Gone on Too Long’ as Competitors Catch Up
After a series of deaths in patients taking Sarepta Therapeutics’ gene therapies, doubt has crept into investor sentiments around the long-time Wall Street darling, and patients may soon begin looking elsewhere.
February 5, 2026
 · 
5 min read
 · 
Dan Samorodnitsky
Successful businessman standing in front of multiple pathways, making a decision for the right move. A symbol of great investment and positive progress in the development of business. stock illustration
Immunology and inflammation
Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I
In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their strategy to expand their GLP-1 franchise into the immunology and inflammation space, with trials currently underway in asthma, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
February 4, 2026
 · 
2 min read
 · 
Heather McKenzie
A stylized image of a hand holding a tray with pills and tablets, symbolizing healthcare, medical treatment, or pharmaceutical services. Minimalist art collage
Earnings
Novo’s Wegovy Pill Success Is ‘Good News’ for Orforglipron, Lilly Execs Say
Novo Nordisk and Eli Lilly both think the Wegovy pill is doing well, but the American rival sees the successful launch as a harbinger of good news for its own candidate, orforglipron, which is expected to hit the market in the second quarter.
February 4, 2026
 · 
2 min read
 · 
Annalee Armstrong
South San Francisco, CA, USA - Feb 23, 2024: Exterior view of AbbVie's research facility in South San Francisco. AbbVie is an American pharmaceutical company headquartered in North Chicago, Illinois.
Earnings
AbbVie’s I&I Portfolio Sells $30 Billion but Execs Again Underline Other Areas
On its fourth quarter earnings call Wednesday, AbbVie CEO Robert Michael called oncology and neuroscience “underappreciated” areas of focus for the pharma.
February 4, 2026
 · 
2 min read
 · 
Dan Samorodnitsky
Facade of Novo Nordisk's office in Fremont, California
Earnings
Novo Goes ‘All In’ on Wegovy Pill but Analysts Worry It’s Not Enough
Novo Nordisk CEO Maziar Mike Doustdar acknowledged the market pressure facing the company’s GLP-1 products but sought to assure investors that Novo has the situation under control.
February 4, 2026
 · 
3 min read
 · 
Annalee Armstrong
3D illustration of tow GLP-1 therapy autoinjectors
Earnings
Amgen Wants MariTide To Change Obesity Paradigm With Longer Dosing Periods
Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its investigational obesity drug MariTide will continue to provide competitive weight loss even at monthly or longer schedules.
February 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Contemporary art collage showing a hand giving a thumbs down surrounded by red arrows pointing down, concept of negative feedback and bad review
Rare diseases
Amgen Will Not Heed FDA Request To Withdraw Rare Disease Drug Tavneos
After review, Amgen is certain that Tavneos is effective and has a favorable benefit-risk profile. The company informed the FDA on January 28 that they would not pull the drug.
February 4, 2026
 · 
2 min read
 · 
Annalee Armstrong
GSK's headquarters office building in Poznan, Poland
Earnings
GSK Says No to GLP-1s, Prioritizes ‘Downstream Effects’ of Obesity
Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently anchored by its Phase III-ready FGF21 analog efimosfermin alfa for liver fibrosis.
February 4, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS